Fact sheet: Variopartner SICAV SeBiOpp

Fund information
Fund name
Variopartner SICAV Sectoral Biotech Opportunities I USD
Fund manager company
Vontobel Asset Management S.A.
Fund type
Offshore Fund
Fund managers
  • Mina Marmorsince 31/05/2016
Fund objective
While respecting the principle of risk diversification, the Sub-Fund's assets are primarily invested in shares, equity-like transferable securities, participation certificates etc. issued by companies worldwide which are active in the generics sector. No geographical restrictions apply re. specific countries or regions.
Benchmark
  • Nasdaq Biotech Index
Investment style
None
Investment method
Shares
Quick stats
1 Year return
-15%
1 Year rank in sector
30/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.19%
Fund size
£67m (£48m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
180
Top in this sector
Fund name1 Year
Variopartner SICAV MVGbMdtcF21.1%
Fidelity Gbl Health Care19.2%
BB Medtech18.1%
Atlantis China Healthcare13.5%
Charlemagne MagnaBiphrm12.3%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA78%
    Money Market13.4%
    Israel4.1%
    Ireland2.5%
    Netherlands1.1%
  • Biotechnology/Medical73.2%
    Money Market13.4%
    Pharmaceuticals13.4%
  • US Equities78%
    Money Market13.4%
    Israeli Equities4.1%
    Irish Equities2.5%
    Dutch Equities1.1%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund6%22.1%15.9%-15%--
Sector1.5%10.5%12.9%-2.3%43.4%140.6%
Rank within sector1 / 322 / 3212 / 3130 / 31--
Quartile1st1st2nd4th
Calendar performance
 YTD - 20162015201420132012
Fund-9.3%----
Sector-2.4%7.2%28.1%41%16.7%
Rank within sector24 / 31----
Quartile4th
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
-
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
-
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
-
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
-
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
-
Price movement
52 week high9.28
52 week low6.21
Current bid price-
Current offer price-
Current mid price8.01
Region
1USA78%
2Money Market13.4%
3Israel4.1%
4Ireland2.5%
5Netherlands1.1%
6France0.9%
Industry sector
1Biotechnology/Medical73.2%
2Money Market13.4%
3Pharmaceuticals13.4%
Asset type
1US Equities78%
2Money Market13.4%
3Israeli Equities4.1%
4Irish Equities2.5%
5Dutch Equities1.1%
6French Equities0.9%
Individual holdings
1NEUROCRINE BIOSCIENCES INC6.4%
2OPHTHOTECH CORP6%
3AMICUS THERAPEUTICS5.7%
4BIOMARIN PHARMACEUTICAL5.6%
5CELGENE CORP5.1%
6ALEXION PHARMACEUTICALS INC4.8%
7NEURODERM LTD4.1%
8NOVAVAX INC4.1%
9PORTOLA PHARMACEUTICALS INC3.6%
Management
Fund manager group
Vontobel Fund Management
Fund manager company
Vontobel Asset Management S.A.
Fund type
Offshore Fund
Fund objective
While respecting the principle of risk diversification, the Sub-Fund's assets are primarily invested in shares, equity-like transferable securities, participation certificates etc. issued by companies worldwide which are active in the generics sector. No geographical restrictions apply re. specific countries or regions.
Benchmark
  • Nasdaq Biotech Index
Investment style
None
Investment method
Shares
Fund managers
NameSinceBiography
Mina Marmor31/05/2016
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, Transparent for German Tax, Reporting Fund Status, UCITS V Compliant
Domicile
No data available.
Fund for sale in
Austria, Switzerland, Germany, France, United Kingdom, Italy, Luxembourg, Offshore
Variopartner SICAV Sectoral Biotech Opportunities I EUR
Initial charge5%
Annual charge0.9%
Min single investment£50,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.19%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price8
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeE2FK
Variopartner SICAV Sectoral Biotech Opportunities I USD
Initial charge5%
Annual charge0.9%
Min single investment£50,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.19%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price8.01
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeE2FJ
Variopartner SICAV Sectoral Biotech Opportunities P EUR
Initial charge5%
Annual charge1.8%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.13%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price7.89
CurrencyEUR
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeE2FL
Variopartner SICAV Sectoral Biotech Opportunities P USD
Initial charge5%
Annual charge1.8%
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)2.13%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price7.9
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeE2FM
Variopartner SICAV Sectoral Biotech Opportunities Z USD
Initial charge5%
Annual charge-
Min single investment£0
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)0.29%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price8.12
CurrencyUSD
Price updated22/09/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeE2FN
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.